Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008

BACKGROUND: Drug resistance of B-cell precursor acute lymphoblastic leukemia (BP-ALL) cells is conferred by both intrinsic and extrinsic factors, which could be targeted to promote chemo-sensitization. Our previous studies showed that Galectin-3, a lectin that clusters galactose-modified glycoprotei...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Clin Cancer Res
Main Authors: Paz, Helicia, Joo, Eun Ji, Chou, Chih-Hsing, Fei, Fei, Mayo, Kevin H., Abdel-Azim, Hisham, Ghazarian, Haike, Groffen, John, Heisterkamp, Nora
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5870532/
https://ncbi.nlm.nih.gov/pubmed/29580262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-018-0721-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados